FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982541306> ?p ?o ?g. }

• W1982541306 endingPage "259" @default.
• W1982541306 startingPage "252" @default.
• W1982541306 abstract "Purpose To report late ocular (primary endpoint) and other toxicity, disease control, and survival (secondary endpoints) after intensity-modulated radiotherapy (IMRT) for sinonasal tumors. Methods and Materials Between 1998 and 2009, 130 patients with nonmetastatic sinonasal tumors were treated with IMRT at Ghent University Hospital. Prescription doses were 70 Gy (n = 117) and 60–66 Gy (n = 13) at 2 Gy per fraction over 6–7 weeks. Most patients had adenocarcinoma (n = 82) and squamous cell carcinoma (n = 23). One hundred and one (101) patients were treated postoperatively. Of 17 patients with recurrent tumors, 9 were reirradiated. T-stages were T1–2 (n = 39), T3 (n = 21), T4a (n = 38), and T4b (n = 22). Esthesioneuroblastoma was staged as Kadish A, B, and C in 1, 3, and 6 cases, respectively. Results Median follow-up was 52, range 15–121 months. There was no radiation-induced blindness in 86 patients available for late toxicity assessment (≥6 month follow-up). We observed late Grade 3 tearing in 10 patients, which reduced to Grade 1–2 in 5 patients and Grade 3 visual impairment because of radiation-induced ipsilateral retinopathy and neovascular glaucoma in 1 patient. There was no severe dry eye syndrome. The worst grade of late ocular toxicity was Grade 3 (n = 11), Grade 2 (n = 31), Grade 1 (n = 33), and Grade 0 (n = 11). Brain necrosis and osteoradionecrosis occurred in 6 and 1 patients, respectively. Actuarial 5-year local control and overall survival were 59% and 52%, respectively. On multivariate analysis local control was negatively affected by cribriform plate and brain invasion (p = 0.044 and 0.029, respectively) and absence of surgery (p = 0.009); overall survival was negatively affected by cribriform plate and orbit invasion (p = 0.04 and <0.001, respectively) and absence of surgery (p = 0.001). Conclusions IMRT for sinonasal tumors allowed delivering high doses to targets at minimized ocular toxicity, while maintaining disease control and survival. Avoidance of severe dry eye syndrome and radiation-induced blindness suggests IMRT as a standard treatment for sinonasal tumors. To report late ocular (primary endpoint) and other toxicity, disease control, and survival (secondary endpoints) after intensity-modulated radiotherapy (IMRT) for sinonasal tumors. Between 1998 and 2009, 130 patients with nonmetastatic sinonasal tumors were treated with IMRT at Ghent University Hospital. Prescription doses were 70 Gy (n = 117) and 60–66 Gy (n = 13) at 2 Gy per fraction over 6–7 weeks. Most patients had adenocarcinoma (n = 82) and squamous cell carcinoma (n = 23). One hundred and one (101) patients were treated postoperatively. Of 17 patients with recurrent tumors, 9 were reirradiated. T-stages were T1–2 (n = 39), T3 (n = 21), T4a (n = 38), and T4b (n = 22). Esthesioneuroblastoma was staged as Kadish A, B, and C in 1, 3, and 6 cases, respectively. Median follow-up was 52, range 15–121 months. There was no radiation-induced blindness in 86 patients available for late toxicity assessment (≥6 month follow-up). We observed late Grade 3 tearing in 10 patients, which reduced to Grade 1–2 in 5 patients and Grade 3 visual impairment because of radiation-induced ipsilateral retinopathy and neovascular glaucoma in 1 patient. There was no severe dry eye syndrome. The worst grade of late ocular toxicity was Grade 3 (n = 11), Grade 2 (n = 31), Grade 1 (n = 33), and Grade 0 (n = 11). Brain necrosis and osteoradionecrosis occurred in 6 and 1 patients, respectively. Actuarial 5-year local control and overall survival were 59% and 52%, respectively. On multivariate analysis local control was negatively affected by cribriform plate and brain invasion (p = 0.044 and 0.029, respectively) and absence of surgery (p = 0.009); overall survival was negatively affected by cribriform plate and orbit invasion (p = 0.04 and <0.001, respectively) and absence of surgery (p = 0.001). IMRT for sinonasal tumors allowed delivering high doses to targets at minimized ocular toxicity, while maintaining disease control and survival. Avoidance of severe dry eye syndrome and radiation-induced blindness suggests IMRT as a standard treatment for sinonasal tumors." @default.
• W1982541306 created "2016-06-24" @default.
• W1982541306 creator A5004288527 @default.
• W1982541306 creator A5011864520 @default.
• W1982541306 creator A5027236935 @default.
• W1982541306 creator A5054186163 @default.
• W1982541306 creator A5057004185 @default.
• W1982541306 creator A5064173789 @default.
• W1982541306 creator A5068664009 @default.
• W1982541306 creator A5073205467 @default.
• W1982541306 creator A5091100826 @default.
• W1982541306 date "2012-05-01" @default.
• W1982541306 modified "2023-10-18" @default.
• W1982541306 title "IMRT for Sinonasal Tumors Minimizes Severe Late Ocular Toxicity and Preserves Disease Control and Survival" @default.
• W1982541306 cites W1980014671 @default.
• W1982541306 cites W1981494590 @default.
• W1982541306 cites W1993577432 @default.
• W1982541306 cites W1995792552 @default.
• W1982541306 cites W2003728267 @default.
• W1982541306 cites W2008167696 @default.
• W1982541306 cites W2009845930 @default.
• W1982541306 cites W2018567163 @default.
• W1982541306 cites W2023597531 @default.
• W1982541306 cites W2024076011 @default.
• W1982541306 cites W2035084321 @default.
• W1982541306 cites W2054267659 @default.
• W1982541306 cites W2062879918 @default.
• W1982541306 cites W2089460299 @default.
• W1982541306 cites W2089885944 @default.
• W1982541306 cites W2098982916 @default.
• W1982541306 cites W2115039828 @default.
• W1982541306 cites W2134065890 @default.
• W1982541306 cites W2141811564 @default.
• W1982541306 cites W2142227180 @default.
• W1982541306 cites W2143942491 @default.
• W1982541306 cites W2156259771 @default.
• W1982541306 cites W4205151458 @default.
• W1982541306 doi "https://doi.org/10.1016/j.ijrobp.2011.06.1977" @default.
• W1982541306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22027259" @default.
• W1982541306 hasPublicationYear "2012" @default.
• W1982541306 type Work @default.
• W1982541306 sameAs 1982541306 @default.
• W1982541306 citedByCount "87" @default.
• W1982541306 countsByYear W19825413062013 @default.
• W1982541306 countsByYear W19825413062014 @default.
• W1982541306 countsByYear W19825413062015 @default.
• W1982541306 countsByYear W19825413062016 @default.
• W1982541306 countsByYear W19825413062017 @default.
• W1982541306 countsByYear W19825413062018 @default.
• W1982541306 countsByYear W19825413062019 @default.
• W1982541306 countsByYear W19825413062020 @default.
• W1982541306 countsByYear W19825413062021 @default.
• W1982541306 countsByYear W19825413062022 @default.
• W1982541306 countsByYear W19825413062023 @default.
• W1982541306 crossrefType "journal-article" @default.
• W1982541306 hasAuthorship W1982541306A5004288527 @default.
• W1982541306 hasAuthorship W1982541306A5011864520 @default.
• W1982541306 hasAuthorship W1982541306A5027236935 @default.
• W1982541306 hasAuthorship W1982541306A5054186163 @default.
• W1982541306 hasAuthorship W1982541306A5057004185 @default.
• W1982541306 hasAuthorship W1982541306A5064173789 @default.
• W1982541306 hasAuthorship W1982541306A5068664009 @default.
• W1982541306 hasAuthorship W1982541306A5073205467 @default.
• W1982541306 hasAuthorship W1982541306A5091100826 @default.
• W1982541306 hasConcept C126322002 @default.
• W1982541306 hasConcept C141071460 @default.
• W1982541306 hasConcept C2781088518 @default.
• W1982541306 hasConcept C29730261 @default.
• W1982541306 hasConcept C509974204 @default.
• W1982541306 hasConcept C71924100 @default.
• W1982541306 hasConceptScore W1982541306C126322002 @default.
• W1982541306 hasConceptScore W1982541306C141071460 @default.
• W1982541306 hasConceptScore W1982541306C2781088518 @default.
• W1982541306 hasConceptScore W1982541306C29730261 @default.
• W1982541306 hasConceptScore W1982541306C509974204 @default.
• W1982541306 hasConceptScore W1982541306C71924100 @default.
• W1982541306 hasIssue "1" @default.
• W1982541306 hasLocation W19825413061 @default.
• W1982541306 hasLocation W19825413062 @default.
• W1982541306 hasOpenAccess W1982541306 @default.
• W1982541306 hasPrimaryLocation W19825413061 @default.
• W1982541306 hasRelatedWork W2026466774 @default.
• W1982541306 hasRelatedWork W2142266070 @default.
• W1982541306 hasRelatedWork W2413129709 @default.
• W1982541306 hasRelatedWork W2418903420 @default.
• W1982541306 hasRelatedWork W2485221435 @default.
• W1982541306 hasRelatedWork W2775091211 @default.
• W1982541306 hasRelatedWork W2915376889 @default.
• W1982541306 hasRelatedWork W4285011532 @default.
• W1982541306 hasRelatedWork W4387359948 @default.
• W1982541306 hasRelatedWork W3145340780 @default.
• W1982541306 hasVolume "83" @default.
• W1982541306 isParatext "false" @default.
• W1982541306 isRetracted "false" @default.
• W1982541306 magId "1982541306" @default.
• W1982541306 workType "article" @default.